James Hsieh.jpg

James J. Hsieh, MD, PhD

Department of Medicine
Oncology Division
Molecular Oncology
Medical Oncology

Clinical Interests

  • Kidney cancer

Research Interests

  • Kidney cancer metabolomics
  • Genomics, Epigenetics
  • Therapeutics, Precision Medicine
  • Translational kidney cancer research
  • Mouse tumor models, Mouse development
  • Drug development
  • Taspase1, Notch, MLL, Stem cells


  • 314-273-1688 (lab)
  • 314-454-8681 (clinic)
  • 314-362-7086 (fax)
  • 554 McDonnell Medical Sciences Building (office/lab)
  • Division of Oncology
    Campus Box 8069
    Washington University Medical School
    660 South Euclid Avenue
    St. Louis, MO 63110

Peer-reviewed Articles

  • Genomic Classifications of Renal Cell Carcinoma: A Critical Step Towards the Future Application of Personalized Kidney Cancer Care With Pan-Omics Precision
    Hsieh JJ, Le V, Cao D, Cheng EH, Creighton CJ
    J Pathol 2017 Dec 19; [Epub ahead of print]
  • Are We Ready for Adjuvant Sunitinib in High-Risk Renal Cell Carcinoma?
    Casuscelli J, Hsieh JJ
    Eur Urol 2018 Jan;73(1):69-70
  • SETD2 Alterations Impair DNA Damage Recognition and Lead to Resistance to Chemotherapy in Leukemia
    Mar BG, Chu SH, Kahn JD, Krivtsov AV, Koche R, Castellano CA, Kotlier JL, Zon RL, McConkey ME, Chabon J, Chappell R, Grauman PV, Hsieh JJ, Armstrong SA, Ebert BL
    Blood 2017 Dec 14;130(24):2631-2641
  • DeltaNp63 Inhibits Oxidative Stress-Induced Cell Death, Including Ferroptosis, and Cooperates With the BCL-2 Family to Promote Clonogenic Survival
    Wang GX, Tu HC, Dong Y, Skanderup AJ, Wang Y, Takeda S, Ganesan YT, Han S, Liu H, Hsieh JJ, Cheng EH
    Cell Rep 2017 Dec 5;21(10):2926-2939
  • Recommendations for the Management of Rare Kidney Cancers
    Giles RH, Choueiri TK, Heng DY, Albiges L, Hsieh JJ, Linehan WM, Pal S, Maskens D, Paseman B, Jonasch E, Malouf G, Molina AM, Pickering L, Shuch B, Srinivas S, Srinivasan R, Tannir NM, Bex A
    Eur Urol 2017 Dec;72(6):974-983
  • Potential Abscopal Response to Dual Checkpoint Blockade in RCC After Reirradiation Using Dose-Painting SBRT
    LaPlant Q, Deselm C, Lockney NA, Hsieh J, Yamada Y
    Pract Radiat Oncol 2017 Nov - Dec;7(6):396-399
  • Characterizing Recurrent and Lethal Small Renal Masses in Clear Cell Renal Cell Carcinoma Using Recurrent Somatic Mutations
    Manley BJ, Reznik E, Ghanaat M, Kashan M, Becerra MF, Casuscelli J, Tennenbaum D, Redzematovic A, Carlo MI, Sato Y, Arcila M, Voss MH, Feldman DR, Motzer RJ, Russo P, Coleman J, Hsieh JJ, Hakimi AA
    Urol Oncol 2017 Nov 10; [Epub ahead of print]
  • Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma
    Becerra MF, Reznik E, Redzematovic A, Tennenbaum DM, Kashan M, Ghanaat M, Casuscelli J, Manley B, Jonsson P, DiNatale RG, Blum KA, Durack JC, Solomon SB, Arcila ME, Bourque C, Socci N, Carlo MI, Lee CH, Voss MH, Feldman DR, Motzer RJ, Coleman JA, Russo P, Cheng EH, Hakimi AA, Hsieh JJ
    Eur Urol Focus 2017 Oct 20; [Epub ahead of print]
  • SWI/SNF Tumor Suppressor Gene PBRM1/BAF180 in Human Clear Cell Kidney Cancer
    Nargund AM, Osmanbeyoglu HU, Cheng EH, Hsieh JJ
    Mol Cell Oncol 2017 Jun 19;4(4):e1342747
  • Genomic Alterations as Predictors of Survival Among Patients Within a Combined Cohort With Clear Cell Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy
    Tennenbaum DM, Manley BJ, Zabor E, Becerra MF, Carlo MI, Casuscelli J, Redzematovic A, Khan N, Arcila ME, Voss MH, Feldman DR, Motzer RJ, Benfante NE, Coleman JA, Russo P, Hsieh JJ, Hakimi AA
    Urol Oncol 2017 Aug;35(8):532e7-532e13
  • Pan-Urologic Cancer Genomic Subtypes That Transcend Tissue of Origin
    Chen F, Zhang Y, Bosse D, Lalani AA, Hakimi AA, Hsieh JJ, Choueiri TK, Gibbons DL, Ittmann M, Creighton CJ
    Nat Commun 2017 Aug 4;8(1):199
  • Benign and Tumor Parenchyma Metabolomic Profiles Affect Compensatory Renal Growth in Renal Cell Carcinoma Surgical Patients
    Rosenzweig B, Rubinstein ND, Reznik E, Shingarev R, Juluru K, Akin O, Hsieh JJ, Jaimes EA, Russo P, Susztak K, Coleman JA, Hakimi AA
    PLoS One 2017 Jul 20;12(7):e0180350
  • Genomic Alterations and Outcomes With VEGF-Targeted Therapy in Patients With Clear Cell Renal Cell Carcinoma
    Carlo MI, Manley B, Patilc S, Woo KM, Coskey DT, Redzematovic A, Arcila M, Ladanyi M, Lee W, Chen YB, Lee CH, Feldman DR, Hakimi AA, Motzer RJ, Hsieh JJ, Voss MH
    Kidney Cancer 2017
  • Targeting the Differential Addiction to Anti-Apoptotic BCL-2 Family for Cancer Therapy
    Inoue-Yamauchi A, Jeng PS, Kim K, Chen HC, Han S, Ganesan YT, Ishizawa K, Jebiwott S, Dong Y, Pietanza MC, Hellmann MD, Kris MG, Hsieh JJ, Cheng EH
    Nat Commun 2017 Jul 17;8:16078
  • Genomic Landscape and Evolution of Metastatic Chromophobe Renal Cell Carcinoma
    Casuscelli J, Weinhold N, Gundem G, Wang L, Zabor EC, Drill E, Wang PI, Nanjangud GJ, Redzematovic A, Nargund AM, Manley BJ, Arcila ME, Donin NM, Cheville JC, Thompson RH, Pantuck AJ, Russo P, Cheng EH, Lee W, Tickoo SK, Ostrovnaya I, Creighton CJ, Papaemmanuil E, Seshan VE, Hakimi AA, Hsieh JJ
    JCI Insight 2017 Jun 15;2(12); [Epub ahead of print]
  • Analysis of Renal Cancer Cell Lines From Two Major Resources Enables Genomics-Guided Cell Line Selection
    Sinha R, Winer AG, Chevinsky M, Jakubowski C, Chen YB, Dong Y, Tickoo SK, Reuter VE, Russo P, Coleman JA, Sander C, Hsieh JJ, Hakimi AA
    Nat Commun 2017 May 10;8:15165
  • Persistent Severe Hyperlactatemia and Metabolic Derangement in Lethal Succinate Dehydrogenase B Mutated Metastatic Kidney Cancer: Clinical Challenges and Examples of Extreme Warburg Effect
    Lee CH, Gundem G, Lee W, Chen YB, Cross JR, Dong Y, Redzematovic A, Mano R, Wei EY, Cheng EH, Srinivasan R, Oschwald D, Hakimi AA, Dunphy MP, Linehan WM, Papaemmanuil E, Hsieh JJ
    J Clin Oncol Precision Oncology 2017
  • Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes
    Carlo MI, Chaim J, Patil S, Kemel Y, Schram AM, Woo K, Coskey D, Nanjangud GJ, Voss MH, Feldman DR, Hsieh JJ, Hakimi AA, Chen YB, Motzer RJ, Lee CH
    Clin Genitourin Cancer 2017 Apr 26; [Epub ahead of print]
  • The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma
    Nargund AM, Pham CG, Dong Y, Wang PI, Osmangeyoglu HU, Xie Y, Aras O, Han S, Oyama T, Takeda S, Ray CE, Dong Z, Berge M, Hakimi AA, Monette S, Lekaye CL, Koutcher JA, Leslie CS, Creighton CJ, Weinhold N, Lee W, Tickoo SK, Wang Z, Cheng EH, Hsieh JJ
    Cell Rep 2017 Mar 21;18(12):2893-2906
  • Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model
    de Velasco G, Culhane AC, Fay AP, Ari Hakimi A, Voss MH, Tannir NM, Tamboli P, Appleman LJ, Bellmunt J, Kimryn Rathmell W, Albiges L, Hsieh JJ, Heng DY, Signoretti S, Choueiri TK
    Oncologist 2017 Mar;22(3):286-292
  • Immune-Related Alopecia (Areata and Universalis) in Cancer Patients Receiving Immune Checkpoint Inhibitors
    Zarbo A, Belum VR, Sibaud V, Oudard S, Postow MA, Hsieh JJ, Motzer RJ, Busam KJ, Lacouture ME
    Br J Dermatol 2017 Jun;176(6):1649-1652
  • Integration of Recurrent Somatic Mutations With Clinical Outcomes: A Pooled Analysis of 1049 Patients With Clear Cell Renal Cell Carcinoma
    Manley BJ, Zabor EC, Casuscelli J, Tennenbaum DM, Redzematovic A, Becerra MF, Benfante N, Sato Y, Morikawa T, Kume H, Fukayama M, Homma Y, Ogawa S, Arcila ME, Voss MH, Feldman DR, Coleman JA, Reuter VE, Motzer RJ, Russo P, Hsieh JJ, Ari Hakimi A
    Eur Urol Focus 2016 Jul 16; [Epub ahead of print]
  • NUP98 Fusion Proteins Interact With the NSL and MLL1 Complexes to Drive Leukemogenesis
    Xu H, Valerio DG, Eisold ME, Sinha A, Koche RP, Hu W, Chen CW, Chu SH, Brien GL, Park CY, Hsieh JJ, Ernst P, Armstrong SA
    Cancer Cell 2016 Dec 12;30(6):863-878
  • Tumor Immune Microenvironment Characterization in Clear Cell Renal Cell Carcinoma Identifies Prognostic and Immunotherapeutically Relevant Messenger RNA Signatures
    Senbabaoglu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, Chen Y, Danilova L, Voss MH, Coleman JA, Russo P, Reuter VE, Chan TA, Cheng EH, Scheinberg DA, Li MO, Choueiri TK, Hsieh JJ, Sander C, Hakimi AA
    Genome Biol 2016 Nov 17;17(1):231
  • Genomic Biomarkers of a Randomized Trial Comparing First-Line Everolimus and Sunitinib in Patients With Metastatic Renal Cell Carcinoma
    Hsieh JJ, Chen D, Wang PI, Marker M, Redzematovic A, Chen YB, Selcuklu SD, Weinhold N, Bouvier N, Huberman KH, Bhanot U, Chevinsky MS, Patel P, Pinciroli P, Won HH, You D, Viale A, Lee W, Hakimi AA, Berger MF, Socci ND, Cheng EH, Knox J, Voss MH, Voi M, Motzer RJ
    Eur Urol 2016 Oct 14; [Epub ahead of print]
  • Molecular Analysis of Aggressive Renal Cell Carcinoma With Unclassified Histology Reveals Distinct Subsets
    Chen YB, Xu J, Skanderup AJ, Dong Y, Brannon AR, Wang L, Won HH, Wang PI, Nanjangud GJ, Jungbluth AA, Li W, Ojeda V, Hakimi AA, Voss MH, Schultz N, Motzer RJ, Russo P, Cheng EH, Giancotti FG, Lee W, Berger MF, Tickoo SK, Reuter VE, Hsieh JJ
    Nat Commun 2016 Oct 7;7:13131
  • Modeling Tumor Growth for Kidney Cancer Based on Nuclei Clusters of Pathology Slides
    Saribudak A, Dong Y, Hsieh JJ, Uyar MU
    Inter J Engineering and Technology 2016 Oct;8(5):375-9
  • Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma
    Voss MH, Molina AM, Chen YB, Woo KM, Chaim JL, Coskey DT, Redzematovic A, Wang P, Lee W, Selcuklu SD, Lee CH, Berger MF, Tickoo SK, Reuter VE, Patil S, Hsieh JJ, Motzer RJ, Feldman DR
    J Clin Oncol 2016 Sep 6; [Epub ahead of print]
  • Tumor Mutational Load and Immune Parameters Across Metastatic Renal Cell Carcinoma Risk Groups
    de Velasco G, Miao D, Voss MH, Hakimi AA, Hsieh JJ, Tannir NM, Tamboli P, Appleman LJ, Rathmell WK, Van Allen EM, Choueiri TK
    Cancer Immunol Res 2016 Oct;4(10):820-822
  • Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma but Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples
    Dong Y, Manley BJ, Becerra MF, Redzematovid A, Casuscelli J, Tennebaum DM, Reznik E, Han S, Benfante N, Chen Y, Arcia ME, Aras O, Voss MH, Feldman DR, Motzer RJ, Fabbri N, Healey JH, Boland PJ, Chawla M, Durack JC, Lee C, Coleman JA, Russo P, Hakimi AA, Cheng EH, Hsieh JJ
    Eur Urol Focus 2016 Aug 24; [Epub ahead of print]
  • Mechanistically Distinct Cancer-Associated mTOR Activation Clusters Predict Sensitivity to Rapamycin
    Xu J, Pham CG, Albanese SK, Dong Y, Oyama T, Lee CH, Rodrik-Outmezguine V, Yao Z, Han S, Chen D, Parton DL, Chodera JD, Rosen N, Cheng EH, Hsieh JJ
    J Clin Invest 2016 Sep 1;126(9):3526-40
  • Integration of Recurrent Somatic Mutations With Clinical Outcomes: A Pooled Analysis of 1049 Clear Cell Renal Cell Carcinoma Patients
    Manley BJ, Zabor EC, Casuscelli J, Tennenbaum DM, Redzematovic A, Becerra MF, Benfante N, Sato Y, Morikawa T, Kume H, Fukayama M, Homma Y, Ogawa S, Arcila ME, Voss MH, Feldman DF, Coleman JA, Reuter VE, Motzer RJ, Russo P, Hsieh JJ, Hakimi AA
    Eur Urol Focus 2016 Jul 16; [Epub ahead of print]
  • A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
    Carlo MI, Molina AM, Lakhman Y, Patil S, Woo K, DeLuca J, Lee CH, Hsieh JJ, Feldman DR, Motzer RJ, Voss MH
    Oncologist 2016 Jul;21(7):787-8
  • Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma
    Chen F, Zhang Y, Senbabaoglu Y, Ciriello G, Yang L, Reznik E, Shuch B, Micevic G, De Velasco G, Shinbrot E, Noble MS, Lu Y, Covington KR, Xi L, Drummond JA, Muzny D, Kang H, Lee J, Tamboli P, Reuter V, Shelley CS, Kaipparettu BA, Bottaro DP, Godwin AK, Gibbs RA, Getz G, Kucherlapati R, Park PJ, Sander C, Henske EP, Zhou JH, Kwiatkowski DJ, Ho TH, Choueiri TK, Hsieh JJ, Akbani R, Mills GB, Hakimi AA, Wheeler DA, Creighton CJ
    Cell Rep 2016 Mar 15;14(10):2476-89
  • Circulating Biomarkers and Outcome From a Randomised Phase II Trial of Sunitinib Vs Everolimus for Patients With Metastatic Renal Cell Carcinoma
    Voss MH, Chen D, Marker M, Hakimi AA, Lee CH, Hsieh JJ, Knox JJ, Voi M, Motzer RJ
    Br J Cancer 2016 Mar 15;114(6):642-9
  • An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma
    Hakimi AA, Reznik E, Lee CH, Creighton CJ, Brannon AR, Luna A, Aksoy BA, Liu EM, Shen R, Lee W, Chen Y, Stirdivant SM, Russo P, Chen YB, Tickoo SK, Reuter VE, Cheng EH, Sander C, Hsieh JJ
    Cancer Cell 2016 Jan 11;29(1):104-16
  • Validation and Genomic Interrogation of the MET Variant Rs11762213 as a Predictor of Adverse Outcomes in Clear Cell Renal Cell Carcinoma
    Hakimi AA, Ostrovnaya I, Jacobsen A, Susztak K, Coleman JA, Russo P, Winer AG, Mano R, Sankin AI, Motzer RJ, Voss MH, Offit K, Purdue M, Pomerantz M, Freedman M, Choueiri TK, Hsieh JJ, Klein RJ
    Cancer 2016 Feb 1;122(3):402-10
  • Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
    Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, Rathmell WK, Brooks AN, Hoadley KA, Robertson AG, Brooks D, Bowlby R, Sadeghi S, Shen H, Weisenberger DJ, Bootwalla M, Baylin SB, Laird PW, Cherniack AD, Saksena G, Haake S, Li J, Liang H, Lu Y, Mills GB, Akbani R, Leiserson MD, Raphael BJ, Anur P, Bottaro D, Albiges L, Barnabas N, Choueiri TK, Czerniak B, Godwin AK, Hakimi AA, Ho TH, Hsieh J, Ittmann M, Kim WY, Krishnan B, Merino MJ, Mills Shaw KR, Reuter VE, Reznik E, Shelley CS, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Tickoo S, Burnett K, Crain D, Gardner J, Lau K, Mallery D, Morris S, Paulauskis JD, Penny RJ, Shelton C, Shelton WT, Sherman M, Thompson E, Yena P, Avedon MT, Bowen J, Gastier-Foster JM, Gerken M, Leraas KM, Lichtenberg TM, Ramirez NC, Santos T, Wise L, Zmuda E, Demchok JA, Felau I, Hutter CM, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Zhang J, Ayala B, Baboud J, Chudamani S, Liu J, Lolla L, Naresh R, Pihl T, Sun Q, Wan Y, Wu Y, Ally A, Balasundaram M, Balu S, Beroukhim R, Bodenheimer T, Buhay C, Butterfield YS, Carlsen R, Carter SL, Chao H, Chuah E, Clarke A, Covington KR, Dahdouli M, Dewal N, Dhalla N, Doddapaneni HV, Drummond JA, Gabriel SB, Gibbs RA, Guin R, Hale W, Hawes A, Hayes DN, Holt RA, Hoyle AP, Jefferys SR, Jones SJ, Jones CD, Kalra D, Kovar C, Lewis L, Li J, Ma Y, Marra MA, Mayo M, Meng S, Meyerson M, Mieczkowski PA, Moore RA, Morton D, Mose LE, Mungall AJ, Muzny D, Parker JS, Perou CM, Roach J, Schein JE, Schumacher SE, Shi Y, Simons JV, Sipahimalani P, Skelly T, Soloway MG, Sougnez C, Tam A, Tan D, Thiessen N, Veluvolu U, Wang M, Wilkerson MD, Wong T, Wu J, Xi L, Zhou J, Bedford J, Chen F, Fu Y, Gerstein M, Haussler D, Kasaian K, Lai P, Ling S, Radenbaugh A, Van Den Berg D, Weinstein JN, Zhu J, Albert M, Alexopoulou I, Andersen JJ, Auman JT, Bartlett J, Bastacky S, Bergsten J, Blute ML, Boice L, Bollag RJ, Boyd J, Castle E, Chen YB, Cheville JC, Curley E, Davies B, DeVolk A, Dhir R, Dike L, Eckman J, Engel J, Harr J, Hrebinko R, Huang M, Huelsenbeck-Dill L, Iacocca M, Jacobs B, Lobis M, Maranchie JK, McMeekin S, Myers J, Nelson J, Parfitt J, Parwani A, Petrelli N, Rabeno B, Roy S, Salner AL, Slaton J, Stanton M, Thompson RH, Thorne L, Tucker K, Weinberger PM, Winemiller C, Zach LA, Zuna R
    N Engl J Med 2016 Jan 14;374(2):135-45
  • The Genomic Landscape of Renal Oncocytoma Identifies a Metabolic Barrier to Tumorigenesis
    Joshi S, Tolkunov D, Aviv H, Hakimi AA, Yao M, Hsieh JJ, Ganesan S, Chan CS, White E
    Cell Rep 2015 Dec 1;13(9):1895-908
  • Genomic Characterisation of Two Cancers of Unknown Primary Cases Supports a Kidney Cancer Origin
    Wei EY, Chen YB, Hsieh JJ
    BMJ Case Rep 2015 Oct 22;2015 pii: bcr2015212685
  • Taspase1 Processing Alters TFIIA Cofactor Properties in the Regulation of TFIID
    Malecova B, Caputo VS, Lee DF, Hsieh JJ, Oelgeschlager T
    Transcription 2015;6(2):21-32
  • An Interconnected Hierarchical Model of Cell Death Regulation by the BCL-2 Family
    Chen HC, Kanai M, Inoue-Yamauchi A, Tu HC, Huang Y, Ren D, Kim H, Takeda S, Reyna DE, Chan PM, Ganesan YT, Liao CP, Gavathiotis E, Hsieh JJ, Cheng EH
    Nat Cell Biol 2015 Oct;17(10):1270-81
  • Mathematical Models of Tumor Growth Using Voronoi Tessellations in Pathology Slides of Kidney Cancer
    Saribudak A, Yiyu Dong, Gundry S, Hsieh J, Uyar MU
    Conf Proc IEEE Eng Med Biol Soc 2015 Aug;2015:4454-7
  • Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis
    Wettersten HI, Hakimi AA, Morin D, Bianchi C, Johnstone ME, Donohoe DR, Trott JF, Aboud OA, Stirdivant S, Neri B, Wolfert R, Stewart B, Perego R, Hsieh JJ, Weiss RH
    Cancer Res 2015 Jun 15;75(12):2541-52
  • TCEB1-Mutated Renal Cell Carcinoma: A Distinct Genomic and Morphological Subtype
    Hakimi AA, Tickoo SK, Jacobsen A, Sarungbam J, Sfakianos JP, Sato Y, Morikawa T, Kume H, Fukayama M, Homma Y, Chen YB, Sankin AI, Mano R, Coleman JA, Russo P, Ogawa S, Sander C, Hsieh JJ, Reuter VE
    Mod Pathol 2015 Jun;28(6):845-53
  • Taspase1-Dependent TFIIA Cleavage Coordinates Head Morphogenesis by Limiting Cdkn2a Locus Transcription
    Takeda S, Sasagawa S, Oyama T, Searleman AC, Westergard TD, Cheng EH, Hsieh JJ
    J Clin Invest 2015 Mar 2;125(3):1203-14
  • Expression of Ror2 Mediates Invasive Phenotypes in Renal Cell Carcinoma
    Rasmussen NR, Debebe Z, Wright TM, Brooks SA, Sendor AB, Brannon AR, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Wallen EM, Simpson C, Norris JL, Janzen WP, Rathmell WK
    PLoS One 2014 Dec 26;9(12):e116101
  • Genomic Investigation of Etiologic Heterogeneity: Methodologic Challenges
    Begg CB, Seshan VE, Zabor EC, Furberg H, Arora A, Shen R, Maranchie JK, Nielsen ME, Rathmell WK, Signoretti S, Tamboli P, Karam JA, Choueiri TK, Hakimi AA, Hsieh JJ
    BMC Med Res Methodol 2014 Dec 22;14:138
  • The Impact of Genetic Heterogeneity on Biomarker Development in Kidney Cancer Assessed by Multiregional Sampling
    Sankin A, Hakimi AA, Mikkilineni N, Ostrovnaya I, Silk MT, Liang Y, Mano R, Chevinsky M, Motzer RJ, Solomon SB, Cheng EH, Durack JC, Coleman JA, Russo P, Hsieh JJ
    Cancer Med 2014 Dec;3(6):1485-92
  • Taspase1 Cleaves MLL1 to Activate Cyclin E for HER2/Neu Breast Tumorigenesis
    Dong Y, Van Tine BA, Oyama T, Wang PI, Cheng EH, Hsieh JJ
    Cell Res 2014 Nov;24(11):1354-66
  • The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma
    Davis CF, Ricketts CJ, Wang M, Yang L, Cherniack AD, Shen H, Buhay C, Kang H, Kim SC, Fahey CC, Hacker KE, Bhanot G, Gordenin DA, Chu A, Gunaratne PH, Biehl M, Seth S, Kaipparettu BA, Bristow CA, Donehower LA, Wallen EM, Smith AB, Tickoo SK, Tamboli P, Reuter V, Schmidt LS, Hsieh JJ, Choueiri TK, Hakimi AA, Chin L, Meyerson M, Kucherlapati R, Park WY, Robertson AG, Laird PW, Henske EP, Kwiatkowski DJ, Park PJ, Morgan M, Shuch B, Muzny D, Wheeler DA, Linehan WM, Gibbs RA, Rathmell WK, Creighton CJ
    Cancer Cell 2014 Sep 8;26(3):319-30
  • Development of Synchronous VHL Syndrome Tumors Reveals Contingencies and Constraints to Tumor Evolution
    Fisher R, Horswell S, Rowan A, Salm MP, de Bruin EC, Gulati S, McGranahan N, Stares M, Gerlinger M, Varela I, Crockford A, Favero F, Quidville V, Andre F, Navas C, Gronroos E, Nicol D, Hazell S, Hrouda D, O'Brien T, Matthews N, Phillimore B, Begum S, Rabinowitz A, Biggs J, Bates PA, McDonald NQ, Stamp G, Spencer-Dene B, Hsieh JJ, Xu J, Pickering L, Gore M, Larkin J, Swanton C
    Genome Biol 2014 Aug 27;15(8):433
  • Proteasome Inhibitors Evoke Latent Tumor Suppression Programs in Pro-B MLL Leukemias Through MLL-AF4
    Liu H, Westergard TD, Cashen A, Piwnica-Worms DR, Kunkle L, Vij R, Pham CG, DiPersio J, Cheng EH, Hsieh JJ
    Cancer Cell 2014 Apr 14;25(4):530-42
  • Tumor Genetic Analyses of Patients With Metastatic Renal Cell Carcinoma and Extended Benefit From mTOR Inhibitor Therapy
    Voss MH, Hakimi AA, Pham CG, Brannon AR, Chen YB, Cunha LF, Akin O, Liu H, Takeda S, Scott SN, Socci ND, Viale A, Schultz N, Sander C, Reuter VE, Russo P, Cheng EH, Motzer RJ, Berger MF, Hsieh JJ
    Clin Cancer Res 2014 Apr 1;20(7):1955-64
  • ClearCode34: A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma
    Brooks SA, Brannon AR, Parker JS, Fisher JC, Sen O, Kattan MW, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Miller CR, Nielsen ME, Rathmell WK
    Eur Urol 2014 Jul;66(1):77-84
  • Impact of Recurrent Copy Number Alterations and Cancer Gene Mutations on the Predictive Accuracy of Prognostic Models in Clear Cell Renal Cell Carcinoma
    Hakimi AA, Mano R, Ciriello G, Gonen M, Mikkilineni N, Sfakianos JP, Kim PH, Motzer RJ, Russo P, Reuter VE, Hsieh JJ, Ostrovnaya I
    J Urol 2014 Jul;192(1):24-9
  • Treatment Outcome With mTOR Inhibitors for Metastatic Renal Cell Carcinoma With Nonclear and Sarcomatoid Histologies
    Voss MH, Bastos DA, Karlo CA, Ajeti A, Hakimi AA, Feldman DR, Hsieh JJ, Molina AM, Patil S, Motzer RJ
    Ann Oncol 2014 Mar;25(3):663-8
  • Radiogenomics of Clear Cell Renal Cell Carcinoma: Associations Between CT Imaging Features and Mutations
    Karlo CA, Di Paolo PL, Chaim J, Hakimi AA, Ostrovnaya I, Russo P, Hricak H, Motzer R, Hsieh JJ, Akin O
    Radiology 2014 Feb;270(2):464-71
  • SQSTM1 Is a Pathogenic Target of 5q Copy Number Gains in Kidney Cancer
    Li L, Shen C, Nakamura E, Ando K, Signoretti S, Beroukhim R, Cowley GS, Lizotte P, Liberzon E, Bair S, Root DE, Tamayo P, Tsherniak A, Cheng SC, Tabak B, Jacobsen A, Hakimi AA, Schultz N, Ciriello G, Sander C, Hsieh JJ, Kaelin WG Jr
    Cancer Cell 2013 Dec 9;24(6):738-50
  • Cleavage of TFIIA by Taspase1 Activates TRF2-Specified Mammalian Male Germ Cell Programs
    Oyama T, Sasagawa S, Takeda S, Hess RA, Lieberman PM, Cheng EH, Hsieh JJ
    Dev Cell 2013 Oct 28;27(2):188-200
  • An Epidemiologic and Genomic Investigation Into the Obesity Paradox in Renal Cell Carcinoma
    Hakimi AA, Furberg H, Zabor EC, Jacobsen A, Schultz N, Ciriello G, Mikklineni N, Fiegoli B, Kim PH, Voss MH, Shen H, Laird PW, Sander C, Reuter VE, Motzer RJ, Hsieh JJ, Russo P
    J Natl Cancer Inst 2013 Dec 18;105(24):1862-70
  • Comprehensive Molecular Characterization of Clear Cell Renal Cell Carcinoma
    Cancer Genome Atlas Research Network (Contributors include: Hsieh JJ)
    Nature 2013 Jul 4;499(7456):43-9
  • Long-Term Response to Sunitinib Therapy for Metastatic Renal Cell Carcinoma
    Molina AM, Jia X, Feldman DR, Hsieh JJ, Ginsberg MS, Velasco S, Patil S, Motzer RJ
    Clin Genitourin Cancer 2013 Sep;11(3):297-302
  • HGF-MET Signals Via the MLL-ETS2 Complex in Hepatocellular Carcinoma
    Takeda S, Liu H, Sasagawa S, Dong Y, Trainor PA, Cheng EH, Hsieh JJ
    J Clin Invest 2013 Jul;123(7):3154-65
  • Adverse Outcomes in Clear Cell Renal Cell Carcinoma With Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network
    Hakimi AA, Ostrovnaya I, Reva B, Schultz N, Chen YB, Gonen M, Liu H, Takeda S, Voss MH, Tickoo SK, Reuter VE, Russo P, Cheng EH, Sander C, Motzer RJ, Hsieh JJ
    Clin Cancer Res 2013 Jun 15;19(12):3259-67
  • PUMA and BIM Are Required for Oncogene Inactivation-Induced Apoptosis
    Bean GR, Ganesan YT, Dong Y, Takeda S, Liu H, Chan PM, Huang Y, Chodosh LA, Zambetti GP, Hsieh JJ, Cheng EH
    Sci Signal 2013 Mar 26;6(268):ra20
  • Epigenetic Expansion of VHL-HIF Signal Output Drives Multiorgan Metastasis in Renal Cancer
    Vanharanta S, Shu W, Brenet F, Hakimi AA, Heguy A, Viale A, Reuter VE, Hsieh JJ, Scandura JM, Massague J
    Nat Med 2013 Jan;19(1):50-6
  • Clinical and Pathologic Impact of Select Chromatin-Modulating Tumor Suppressors in Clear Cell Renal Cell Carcinoma
    Hakimi AA, Chen YB, Wren J, Gonen M, Abdel-Wahab O, Heguy A, Liu H, Takeda S, Tickoo SK, Reuter VE, Voss MH, Motzer RJ, Coleman JA, Cheng EH, Russo P, Hsieh JJ
    Eur Urol 2013 May;63(5):848-54
  • A Pharmacologic Inhibitor of the Protease Taspase1 Effectively Inhibits Breast and Brain Tumor Growth
    Chen DY, Lee Y, Van Tine BA, Searleman AC, Westergard TD, Liu H, Tu HC, Takeda S, Dong Y, Piwnica-Worms DR, Oh KJ, Korsmeyer SJ, Hermone A, Gussio R, Shoemaker RH, Cheng EH, Hsieh JJ
    Cancer Res 2012 Feb 1;72(3):736-46
  • The Ability of MLL to Bind RUNX1 and Methylate H3K4 at PU.1 Regulatory Regions Is Impaired by MDS/AML-Associated RUNX1/AML1 Mutations
    Huang G, Zhao X, Wang L, Elf S, Xu H, Zhao X, Sashida G, Zhang Y, Liu Y, Lee J, Menendez S, Yang Y, Yan X, Zhang P, Tenen DG, Osato M, Hsieh JJ, Nimer SD
    Blood 2011 Dec 15;118(25):6544-52
  • BID, BIM, and PUMA Are Essential for Activation of the BAX- And BAK-Dependent Cell Death Program
    Ren D, Tu HC, Kim H, Wang GX, Bean GR, Takeuchi O, Jeffers JR, Zambetti GP, Hsieh JJ, Cheng EH
    Science 2010 Dec 3;330(6009):1390-3
  • Phosphorylation of MLL by ATR Is Required for Execution of Mammalian S-Phase Checkpoint
    Liu H, Takeda S, Kumar R, Westergard TD, Brown EJ, Pandita TK, Cheng EH, Hsieh JJ
    Nature 2010 Sep 16;467(7313):343-6
  • Taspase1 Functions as a Non-Oncogene Addiction Protease That Coordinates Cancer Cell Proliferation and Apoptosis
    Chen DY, Liu H, Takeda S, Tu HC, Sasagawa S, Van Tine BA, Lu D, Cheng EH, Hsieh JJ
    Cancer Res 2010 Jul 1;70(13):5358-67
  • Stepwise Activation of BAX and BAK by TBID, BIM, and PUMA Initiates Mitochondrial Apoptosis
    Kim H, Tu HC, Ren D, Takeuchi O, Jeffers JR, Zambetti GP, Hsieh JJ, Cheng EH
    Mol Cell 2009 Nov 13;36(3):487-99
  • miR-128b Is a Potent Glucocorticoid Sensitizer in MLL-AF4 Acute Lymphocytic Leukemia Cells and Exerts Cooperative Effects With miR-221
    Kotani A, Ha D, Hsieh J, Rao PK, Schotte D, den Boer ML, Armstrong SA, Lodish HF
    Blood 2009 Nov 5;114(19):4169-78
  • The VDAC2-BAK Rheostat Controls Thymocyte Survival
    Ren D, Kim H, Tu HC, Westergard TD, Fisher JK, Rubens JA, Korsmeyer SJ, Hsieh JJ, Cheng EH
    Sci Signal 2009 Aug 25;2(85):ra48
  • Design, Syntheses, and Evaluation of Taspase1 Inhibitors
    Lee JT, Chen DY, Yang Z, Ramos AD, Hsieh JJ, Bogyo M
    Bioorg Med Chem Lett 2009 Sep 1;19(17):5086-90
  • The p53-Cathepsin Axis Cooperates With ROS to Activate Programmed Necrotic Death Upon DNA Damage
    Tu HC, Ren D, Wang GX, Chen DY, Westergard TD, Kim H, Sasagawa S, Hsieh JJ, Cheng EH
    Proc Natl Acad Sci U S A 2009 Jan 27;106(4):1093-8
  • PRMT6-Mediated Methylation of R2 in Histone H3 Antagonizes H3 K4 Trimethylation
    Hyllus D, Stein C, Schnabel K, Schiltz E, Imhof A, Dou Y, Hsieh J, Bauer UM
    Genes Dev 2007 Dec 15;21(24):3369-80
  • Bimodal Degradation of MLL by SCFSkp2 and APCCdc20 Assures Cell Cycle Execution: A Critical Regulatory Circuit Lost in Leukemogenic MLL Fusions
    Liu H, Cheng EH, Hsieh JJ
    Genes Dev 2007 Oct 1;21(19):2385-98
  • Species Selectivity of Mixed-Lineage Leukemia/Trithorax and HCF Proteolytic Maturation Pathways
    Capotosti F, Hsieh JJ, Herr W
    Mol Cell Biol 2007 Oct;27(20):7063-72
  • Hierarchical Regulation of Mitochondrion-Dependent Apoptosis by BCL-2 Subfamilies
    Kim H, Rafiuddin-Shah M, Tu HC, Jeffers JR, Zambetti GP, Hsieh JJ, Cheng EH
    Nat Cell Biol 2006 Dec;8(12):1348-58
  • Proteolysis of MLL Family Proteins Is Essential for Taspase1-Orchestrated Cell Cycle Progression
    Takeda S, Chen DY, Westergard TD, Fisher JK, Rubens JA, Sasagawa S, Kan JT, Korsmeyer SJ, Cheng EH, Hsieh JJ
    Genes Dev 2006 Sep 1;20(17):2397-409
  • Uncleaved TFIIA Is a Substrate for Taspase 1 and Active in Transcription
    Zhou H, Spicuglia S, Hsieh JJ, Mitsiou DJ, Hoiby T, Veenstra GJ, Korsmeyer SJ, Stunnenberg HG
    Mol Cell Biol 2006 Apr;26(7):2728-35
  • Taspase1: A Threonine Aspartase Required for Cleavage of MLL and Proper HOX Gene Expression
    Hsieh JJ, Cheng EH, Korsmeyer SJ
    Cell 2003 Oct 31;115(3):293-303
  • Proteolytic Cleavage of MLL Generates a Complex of N- And C-Terminal Fragments That Confers Protein Stability and Subnuclear Localization
    Hsieh JJ, Ernst P, Erdjument-Bromage H, Tempst P, Korsmeyer SJ
    Mol Cell Biol 2003 Jan;23(1):186-94
  • A Secreted Delta1-Fc Fusion Protein Functions Both as an Activator and Inhibitor of Notch1 Signaling
    Hicks C, Ladi E, Lindsell C, Hsieh JJ, Hayward SD, Collazo A, Weinmaster G
    J Neurosci Res 2002 Jun 15;68(6):655-67
  • SKIP, a CBF1-Associated Protein, Interacts With the Ankyrin Repeat Domain of NotchIC to Facilitate NotchIC Function
    Zhou S, Fujimuro M, Hsieh JJ, Chen L, Miyamoto A, Weinmaster G, Hayward SD
    Mol Cell Biol 2000 Apr;20(7):2400-10
  • A Role for SKIP in EBNA2 Activation of CBF1-Repressed Promoters
    Zhou S, Fujimuro M, Hsieh JJ, Chen L, Hayward SD
    J Virol 2000 Feb;74(4):1939-47
  • CIR, a Corepressor Linking the DNA Binding Factor CBF1 to the Histone Deacetylase Complex
    Hsieh JJ, Zhou S, Chen L, Young DB, Hayward SD
    Proc Natl Acad Sci U S A 1999 Jan 5;96(1):23-8
  • Epstein-Barr Virus Immortalization: Notch2 Interacts With CBF1 and Blocks Differentiation
    Hsieh JJ, Nofziger DE, Weinmaster G, Hayward SD
    J Virol 1997 Mar;71(3):1938-45
  • Notch Signaling Inhibits Muscle Cell Differentiation Through a CBF1-Independent Pathway
    Shawber C, Nofziger D, Hsieh JJ, Lindsell C, Bogler O, Hayward D, Weinmaster G
    Development 1996 Dec;122(12):3765-73
  • Truncated Mammalian Notch1 Activates CBF1/RBPJk-Repressed Genes by a Mechanism Resembling That of Epstein-Barr Virus EBNA2
    Hsieh JJ, Henkel T, Salmon P, Robey E, Peterson MG, Hayward SD
    Mol Cell Biol 1996 Mar;16(3):952-9
  • Masking of the CBF1/RBPJ Kappa Transcriptional Repression Domain by Epstein-Barr Virus EBNA2
    Hsieh JJ, Hayward SD
    Science 1995 Apr 28;268(5210):560-3
  • EBNA-2 Upregulation of Epstein-Barr Virus Latency Promoters and the Cellular CD23 Promoter Utilizes a Common Targeting Intermediate, CBF1
    Ling PD, Hsieh JJ, Ruf IK, Rawlins DR, Hayward SD
    J Virol 1994 Sep;68(9):5375-83